Gert Van den Eynden, Ph.D.
Affiliations: | 2008 | Universiteit Antwerpen (Belgium) |
Area:
Pathology, OncologyGoogle:
"Gert Van den Eynden"Parents
Sign in to add mentor| P B. Vermeulen | grad student | 2008 | Universiteit Antwerpen (Belgium) | |
| (Hypoxia, angiogenesis and lymphangiogenesis at different sites in breast cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fimereli D, Venet D, Rediti M, et al. (2022) Timing evolution of lobular breast cancer through phylogenetic analysis. Ebiomedicine. 82: 104169 |
| Gómez-Aleza C, Nguyen B, Yoldi G, et al. (2020) Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nature Communications. 11: 6335 |
| Richard F, Majjaj S, Venet D, et al. (2020) Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Sonnenblick A, Salmon-Divon M, Salgado R, et al. (2020) Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. International Journal of Cancer |
| Nederlof I, De Bortoli D, Bareche Y, et al. (2019) Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. Breast Cancer Research : Bcr. 21: 151 |
| Desmedt C, Pingitore J, Rothé F, et al. (2019) mutations in metastatic lobular breast cancer patients. Npj Breast Cancer. 5: 9 |
| Smid M, Wilting S, Uhr K, et al. (2019) The circular RNome of primary breast cancer. Genome Research |
| Nik-Zainal S, Davies H, Staaf J, et al. (2019) Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature |
| Mayrhofer M, De Laere B, Whitington T, et al. (2018) Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine. 10: 85 |
| De Laere B, Oeyen S, Mayrhofer M, et al. (2018) TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |